X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GSK Pharma Fact Sheet, GSK Pharma Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK Pharma Fact Sheet   (GLXO)

Here is the latest financial fact sheet of GSK Pharma. For more details, see the GSK Pharma quarterly results and GSK Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

GSK PHARMA Price History

Price Rs 2,775.0
Mkt Cap Rs m 235,043
Vol '000 0.7
P/E X 66.8
P/CF X 60.5
EPS (TTM) Rs 41.6
% ch % 0.4
No. of shares m 84.70
% ch week % -2.4
% ch 1-mth % -0.6
% ch 12-mth % 8.6
52 week H/L Rs 2,990.0/2,040.0
(As on Jul 20, 2018 03:37:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

GSK PHARMA Financials

No. of Mths
Year Ending
12
Dec-13
15
Mar-15
12
Mar-16
12
Mar-17
12
Mar-18
5-Yr Chart
Click to enlarge
GSK PHARMA EQUITY SHARE DATA
High Rs3,0023,5503,8503,8382,760 
Low Rs2,0052,3522,9662,6372,040 
Sales per share (Unadj.) Rs302.6396.5335.1343.4339.0 
Earnings per share (Unadj.) Rs56.955.744.439.841.4 
Diluted earnings per shareRs56.955.744.439.841.4 
Cash flow per share (Unadj.) Rs59.258.747.442.945.9 
Dividends per share (Unadj.) Rs50.0062.5050.0030.0035.00 
Adj. dividends per shareRs50.0062.5050.0030.0035.00 
Dividend yield (eoy) %2.02.11.50.91.5 
Book value per share (Unadj.) Rs234.9288.6257.8236.9242.9 
Adj. book value per shareRs234.9288.6257.8236.9242.9 
Shares outstanding (eoy) m84.7084.7084.7084.7084.70 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x8.37.410.29.47.1 
Avg P/E ratio x44.053.076.781.457.9 
P/CF ratio (eoy) x42.350.372.075.552.3 
Price / Book Value ratio x10.710.213.213.79.9 
Dividend payout %87.9112.2112.675.484.5 
Avg Mkt Cap Rs m212,038249,933288,643274,216203,280 
No. of employees `0005.04.74.64.7NA 
Total wages/salary Rs m3,6214,9304,4344,8305,234 
Avg. sales/employee Rs Th5,090.87,211.76,154.76,192.2NM 
Avg. wages/employee Rs Th719.31,058.6961.61,028.3NM 
Avg. net profit/employee Rs Th956.91,012.7815.8717.1NM 
GSK PHARMA INCOME DATA
Net Sales Rs m25,62733,58528,37929,08528,715 
Other income Rs m1,7701,9991,228731545 
Total revenues Rs m27,39735,58429,60729,81629,260 
Gross profit Rs m5,2826,2834,7834,1905,059 
Depreciation Rs m199254250263380 
Interest Rs m00032 
Profit before tax Rs m6,8538,0285,7614,6555,222 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m262-51923457178 
Tax Rs m2,2982,7932,0231,7441,892 
Profit after tax Rs m4,8174,7163,7613,3683,508 
Gross profit margin %20.618.716.914.417.6 
Effective tax rate %33.534.835.137.536.2 
Net profit margin %18.814.013.311.612.2 
GSK PHARMA BALANCE SHEET DATA
Current assets Rs m26,23925,87021,73716,74221,815 
Current liabilities Rs m8,8895,0025,7927,20215,999 
Net working cap to sales %67.762.156.232.820.3 
Current ratio x3.05.23.82.31.4 
Inventory Days Days4941685364 
Debtors Days Days1411162119 
Net fixed assets Rs m1,6202,4444,7778,63512,475 
Share capital Rs m847847847847847 
"Free" reserves Rs m19,03323,59420,98519,22219,726 
Net worth Rs m19,89724,44121,83220,06920,573 
Long term debt Rs m362616106 
Total assets Rs m31,29532,24430,54930,03839,475 
Interest coverage xNMNMNM1,552.72,612.0 
Debt to equity ratio x00000 
Sales to assets ratio x0.81.00.91.00.7 
Return on assets %15.414.612.311.28.9 
Return on equity %24.219.317.216.817.1 
Return on capital %35.730.726.525.526.2 
Exports to sales %0.40.2000 
Imports to sales %12.312.914.900 
Exports (fob) Rs m9563400 
Imports (cif) Rs m3,1594,3344,23700 
Fx inflow Rs m625699519528564 
Fx outflow Rs m5,3807,6808,3207,1937,429 
Net fx Rs m-4,755-6,981-7,801-6,665-6,865 
GSK PHARMA CASH FLOW
From Operations Rs m 2,813 3,409 1,389 2,344 4,728 
From Investments Rs m 1,890 1,776 4,990 3,006 -1,042 
From Financial Activity Rs m -4,941 -4,970 -6,383 -5,108 -3,066 
Net Cashflow Rs m -239 215 -4 242 620 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 0.0%
Foreign collaborators 50.7%
Indian inst/Mut Fund 10.2%
FIIs 23.8%
ADR/GDR 0.0%
Free float 15.4%
Shareholders 102,036
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Dr. Annie Besant Road, Worli, Mumbai - 400 030
E-MAIL ajay.a.nadkarni@gsk.com WEB www.gsk-india.com
TELEPHONE (022) 2495 9415 FAX (022) 2498 1526
SECTOR PHARMACEUTICALS GROUP M N C
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR Price Waterhouse & Co.
CHM: D. S. Parekh COMP SEC: A. A. Nadkarni (GM & Admin) YEAR OF INC: 1924 BSE CODE: 500660 FV (Rs): 10 DIV YIELD (%): 1.3

More Pharmaceuticals Company Fact Sheets:   AMAR REMEDIES  AJANTA PHARMA  SUN PHARMA  CIPLA  ALEMBIC LTD  

Compare GSK PHARMA With:   AMAR REMEDIES  AJANTA PHARMA  SUN PHARMA  CIPLA  ALEMBIC LTD  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; IT Stocks Lead Gains(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day in above the dotted line.

Views on news

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

ICICI Pru Mutual Fund Tarakki Karega! - The Unethical Way?(Outside View)

Jul 11, 2018

PersonalFN explains how ICICI Prudential Mutual Fund flouted the norms of related party transactions while subscribing to the IPO of ICICI Securities.

PPF v/s Mutual Funds: Which Is Better?(Outside View)

Jul 10, 2018

PersonalFN highlights the key points of distinction between PPF and mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GSK PHARMA

GSK PHARMA - PANACEA BIOTECH COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS